Literature DB >> 22527019

TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma.

C Eloy1, J Santos, J Cameselle-Teijeiro, P Soares, M Sobrinho-Simões.   

Abstract

Poorly circumscribed growth pattern, extra-thyroid extension and high intratumoural lymph vessel density are significantly associated to nodal metastatization in papillary thyroid carcinoma (PTC). It was also shown that transforming growth factor beta (TGF-beta)/Smad-dependent pathway activity is associated with local invasion, nodal metastatization and BRAF-mutated PTCs. We analysed the immunoexpression of TGF-beta, Smad2/Smad3, Smad4 and Smad7 in a series of 42 cases of classic PTC and 33 cases of follicular variant of PTC with known clinico-pathological and follow-up data, as well as BRAF and RAS status. The 75 PTCs were divided into poorly circumscribed (PCPTC) (n = 53) and well circumscribed (WCPTC) (n = 22) according to their borders. Nodal metastases were not detected in any WCPTC regardless of the presence of immunoexpression for TGF-beta, Smad2/Smad3, Smad4 and Smad7 and occurrence of BRAF mutation (in 20 % of WCPTCs). Increased cytoplasmatic expression of TGF-beta at the periphery of PCPTC was associated to morphological features of invasiveness, featuring the so-called epithelial-to-mesenchymal transition (EMT), and presence of nodal metastases, as well as to the occurrence of BRAF mutation which did not significantly alter, per se, the frequency of nodal metastases. The nuclear expression of Smad7 was more frequent in WCPTCs than in PCPTCs and was associated with unicentricity and absence of extra-thyroid extension, vascular invasion and nodal metastases. We conclude that nodal metastases are associated to poorly circumscribed, locally invasive PTCs that exhibit low levels of nuclear Smad7 and a peripheral EMT phenotype displaying TGF-beta overexpression, regardless of the occurrence of BRAF mutation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22527019     DOI: 10.1007/s00428-012-1234-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  55 in total

Review 1.  Role of integrins in cell invasion and migration.

Authors:  John D Hood; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

2.  Lack of responsiveness to TGF-beta1 in a thyroid carcinoma cell line with functional type I and type II TGF-beta receptors and Smad proteins, suggests a novel mechanism for TGF-beta insensitivity in carcinoma cells.

Authors:  N E Heldin; D Bergström; A Hermansson; A Bergenstråhle; A Nakao; B Westermark; P ten Dijke
Journal:  Mol Cell Endocrinol       Date:  1999-07-20       Impact factor: 4.102

3.  In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid cancer.

Authors:  A Fiumara; A Belfiore; G Russo; E Salomone; G M Santonocito; O Ippolito; R Vigneri; P Gangemi
Journal:  J Clin Endocrinol Metab       Date:  1997-05       Impact factor: 5.958

4.  Epithelial rat thyroid cell clones, escaping from transforming growth factor beta negative growth control, are still inhibited by this factor in the ability to trap iodide.

Authors:  A Coppa; G Mincione; S Mammarella; A Ranieri; G Colletta
Journal:  Cell Growth Differ       Date:  1995-03

5.  Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition.

Authors:  Zhiyan Liu; Kennichi Kakudo; Yanhua Bai; Yaqiong Li; Takashi Ozaki; Akira Miyauchi; Emiko Taniguchi; Ichiro Mori
Journal:  J Clin Pathol       Date:  2011-02-04       Impact factor: 3.411

6.  Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

Authors:  F D Gilliland; W C Hunt; D M Morris; C R Key
Journal:  Cancer       Date:  1997-02-01       Impact factor: 6.860

7.  A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours.

Authors:  Davide Lazzereschi; Francesco Nardi; Alessandra Turco; Laura Ottini; Cristina D'Amico; Renato Mariani-Costantini; Alberto Gulino; Anna Coppa
Journal:  Oncogene       Date:  2005-08-11       Impact factor: 9.867

8.  Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion.

Authors:  Vasily Vasko; Allan V Espinosa; William Scouten; Huiling He; Herbert Auer; Sandya Liyanarachchi; Alexander Larin; Victoria Savchenko; Gary L Francis; Albert de la Chapelle; Motoyasu Saji; Matthew D Ringel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-12       Impact factor: 11.205

9.  Transforming growth factor beta1 induces nuclear export of inhibitory Smad7.

Authors:  S Itóh; M Landström; A Hermansson; F Itoh; C H Heldin; N E Heldin; P ten Dijke
Journal:  J Biol Chem       Date:  1998-10-30       Impact factor: 5.157

10.  TGFB, TGFB Receptors, Ki-67, and p27(Kip)l Expression in Papillary Thyroid Carcinomas.

Authors:  Ricardo V. Lloyd; Jorge A. Ferreiro; Long Jin; Tom J. Sebo
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

View more
  17 in total

1.  High iodine blocks a Notch/miR-19 loop activated by the BRAF(V600E) oncoprotein and restores the response to TGFβ in thyroid follicular cells.

Authors:  Cesar Seigi Fuziwara; Edna Teruko Kimura
Journal:  Thyroid       Date:  2014-01-29       Impact factor: 6.568

2.  The role of epithelial mesenchymal transition markers in thyroid carcinoma progression.

Authors:  Celina Montemayor-Garcia; Heather Hardin; Zhenying Guo; Carolina Larrain; Darya Buehler; Sofia Asioli; Herbert Chen; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

Review 3.  The immune network in thyroid cancer.

Authors:  Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

4.  MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma.

Authors:  Zhihong Wang; Hao Zhang; Ping Zhang; Wenwu Dong; Liang He
Journal:  Tumour Biol       Date:  2015-12-19

5.  Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers.

Authors:  Tara Jarboe; Neha Y Tuli; Sanjukta Chakraborty; Rachana R Maniyar; Nicole DeSouza; Augustine Moscatello; Jan Geliebter; Raj K Tiwari
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Morphology predicts BRAF (V⁶⁰⁰E) mutation in papillary thyroid carcinoma: an interobserver reproducibility study.

Authors:  Renu K Virk; Constantine G A Theoharis; Avinash Prasad; David Chhieng; Manju L Prasad
Journal:  Virchows Arch       Date:  2014-02-19       Impact factor: 4.064

7.  Notch and TGF-β/Smad3 pathways are involved in the interaction between cancer cells and cancer-associated fibroblasts in papillary thyroid carcinoma.

Authors:  Jie Zhang; Yuan Wang; Dan Li; Shanghua Jing
Journal:  Tumour Biol       Date:  2013-08-06

8.  FoxP3 in papillary thyroid carcinoma induces NIS repression through activation of the TGF-β1/Smad signaling pathway.

Authors:  Siyuan Ma; Qingzhu Wang; Xiaojun Ma; Lina Wu; Feng Guo; Hongfei Ji; Fei Liu; Yanyan Zhao; Guijun Qin
Journal:  Tumour Biol       Date:  2015-08-12

Review 9.  Immune Landscape of Thyroid Cancers: New Insights.

Authors:  Elisa Menicali; Martina Guzzetti; Silvia Morelli; Sonia Moretti; Efisio Puxeddu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-27       Impact factor: 5.555

10.  Appreciating the broad clinical features of SMAD4 mutation carriers: a multicenter chart review.

Authors:  Karen E Wain; Marissa S Ellingson; Jamie McDonald; Amanda Gammon; Maegan Roberts; Pavel Pichurin; Ingrid Winship; Douglas L Riegert-Johnson; Jeffrey N Weitzel; Noralane M Lindor
Journal:  Genet Med       Date:  2014-02-13       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.